Previous 10 | Next 10 |
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences Cowen Health Care Conference Needham Virtual Neuroscience Forum PR Newswire DUBLIN , Feb. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the ...
Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022 PR Newswire DUBLIN , Feb. 15, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 fourth quarter and...
The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...
Jazz Pharmaceuticals laid out its 2025 vision at the J.P. Morgan Healthcare Conference last month. The company expects to generate $5 billion in revenues in 2025 and a five percentage points operating margin improvement. The margin goal seems achievable but there are risks on the ...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Jazz Pharmaceuticals faces increased competition after a competitor was able to manufacture a generic version of their Narcolepsy drug Xyrem. The market for Narcolepsy, which is Jazz Pharm’s best-performing drug market, has a stable yet extremely slow growth rate. The compa...
Jazz Pharmaceuticals (JAZZ -0.5%) completed the submission of a supplemental biologics license application to the U.S. Food and Drug Administration seeking approval for a Monday/Wednesday/Friday intramuscular dosing schedule for Rylaze for use as a component of a multi-agent chemotherape...
Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule Phase 2/3 trial data, the basis for submission, demonstrates Rylaze maintains a cl...
The cannabis industry performed horribly in 2021. The Horizons Marijuana Life Sciences ETF , an industry benchmark, has dropped by a little more than 50% over the past 12 months, and many of the top players in the sector didn't do much better. Still, the pot market in North Amer...
The past two years have been hectic, to say the least, largely due to the COVID-19 pandemic. While we've made some progress on that front, the outbreak is far from over. We are currently experiencing a surge in cases due to the omicron variant of the virus. How will things evolve in 2022? I...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...